Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the transcript. The company reported having a surplus cash balance of around Rs. 235 crores as of September 30, 2025, indicating a strong liquidity position. Discussions around capital expenditure indicate internal funding plans (Rs.160 crores CAPEX for FY26 and Rs.100-120 crores for FY27), without reference to external fundraising. No questions or management comments suggest any intention to raise funds via equity or debt in the near future. Overall, Vijaya Diagnostic Centre Limited appears to be financially s

Any current/future capex/capital investment/strategic investment?

FY26 CAPEX for new centres is about Rs.160 crores, majority incurred by H1FY26. FY27 CAPEX expected between Rs.100 to Rs.120 crores, lower than FY26. CAPEX focused on opening new hubs and spokes in various geographies including Bangalore, Kolkata, Pune, and core markets. Two hubs opened recently in Nandyal and Khammam; two more hubs planned in Q3 FY26. Plans to increase hubs from current two to five by end of FY27. Long-term expansion plan includes lease properties for new hubs/spokes. Break-even for new centres generally expected within one year. Strategic investment in technology planned wit

Future growth expectations in sales/revenue/volumes?

Vijaya Diagnostic Centre targets around 15% overall year-level growth. Radiology volume growth guidance is around 13%, with realization growth of 1.5-2%. Growth is volume-driven across new geographies (Bangalore, Kolkata, Pune), especially in initial 1-1.5 years, with limited price hikes expected near-term. Multiple new hubs and spokes expected to be operational, increasing volume and contribution from advanced radiology. Bangalore hubs expected to grow by volume for 1-1.5 years; some hubs have broken even earlier. Pune hubs expected to break even within about a year; some cleanup activities d

Future growth expectations in earnings/operating earnings/profits/EPS?

Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this. EBITDA margins are expected to be around 40% for FY27, slightly improving as new centers break even. CAPEX for FY27 is anticipated between Rs.100 to Rs.120 crores, lower than FY26’s Rs.160 crores, supporting margin expansion. Break-even for new hubs is targeted within one year, with some new centers achieving earlier break-even. Growth is expected to be volume-driven across new geographies (Bangalore, Kolkata, Pune) for the next 1–1.5 years, with limited

IN US

Sale is live|00:00:00left today

Vijaya Diagnostic Centre LtdQ3 FY25Healthcare Services

Vijaya Diagnostic Centre Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,288P/E: 79.1Market Cap: ₹13.7K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Vijaya Diagnostic Centre targets around 15% overall year-level growth.
→Radiology volume growth guidance is around 13%, with realization growth of 1.5-2%.
→Growth is volume-driven across new geographies (Bangalore, Kolkata, Pune), especially in initial 1-1.5 years, with limited price hikes expected near-term.
→Multiple new hubs and spokes expected to be operational, increasing volume and contribution from advanced radiology.
→Bangalore hubs expected to grow by volume for 1-1.5 years; some hubs have broken even earlier.
→Pune hubs expected to break even within about a year; some cleanup activities delayed ramp-up.
→Despite seasonality and weather factors impacting pathology volumes temporarily, the company is optimistic on steady normalized growth.
→Strategic location choice and differentiation expected to bolster growth against competition.
→The company is confident of surpassing prior guidance on revenue and EBITDA margin in coming periods.

Margin guidance

Category 3

→Vijaya Diagnostic Centre projects around 15% CAGR revenue growth over the next three years, with efforts ongoing to potentially exceed this.
→EBITDA margins are expected to be around 40% for FY27, slightly improving as new centers break even.
→CAPEX for FY27 is anticipated between Rs.100 to Rs.120 crores, lower than FY26’s Rs.160 crores, supporting margin expansion.
→Break-even for new hubs is targeted within one year, with some new centers achieving earlier break-even.
→Growth is expected to be volume-driven across new geographies (Bangalore, Kolkata, Pune) for the next 1–1.5 years, with limited price hikes unless input costs necessitate.
→The company remains confident about surpassing current EBITDA margin guidance, having delivered ~39.2% in recent quarters vs. guided 38%-39%.
→Early signs indicate strong radiology growth (~16%) and improved operations post-expansion support promising operating earnings growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the transcript.
→The company reported having a surplus cash balance of around Rs. 235 crores as of September 30, 2025, indicating a strong liquidity position.
→Discussions around capital expenditure indicate internal funding plans (Rs.160 crores CAPEX for FY26 and Rs.100-120 crores for FY27), without reference to external fundraising.
→No questions or management comments suggest any intention to raise funds via equity or debt in the near future.
→Overall, Vijaya Diagnostic Centre Limited appears to be financially self-sufficient with no immediate plans for fundraising.

Order book

The transcript from Vijaya Diagnostic Centre Limited's earnings call on November 4, 2025, does not explicitly mention a current or expected order book or pending orders. However, relevant insights include: - The company is actively expanding through opening new hubs and spokes across various cities like Bangalore, Pune, Kolkata, and Hyderabad. - They plan to add 4-5 hubs and 10-12 spokes by the end of FY26. - CAPEX for H2FY26 stands at Rs.160 crores (mostly incurred in H1), with an expected Rs.100-120 crores CAPEX planned for FY27. - Focus is on stabilizing new centers before further expansion, especially in Pune. - Growth is driven by volume increase rather than pricing hikes. - No direct figures or guidance on order book or pending orders were disclosed in the call.

Capex plans

Yes

→FY26 CAPEX for new centres is about Rs.160 crores, majority incurred by H1FY26.
→FY27 CAPEX expected between Rs.100 to Rs.120 crores, lower than FY26.
→CAPEX focused on opening new hubs and spokes in various geographies including Bangalore, Kolkata, Pune, and core markets.
→Two hubs opened recently in Nandyal and Khammam; two more hubs planned in Q3 FY26.
→Plans to increase hubs from current two to five by end of FY27.
→Long-term expansion plan includes lease properties for new hubs/spokes.
→Break-even for new centres generally expected within one year.
→Strategic investment in technology planned with the recruitment of a new CTO to enhance IT and operational capabilities.

How does Vijaya Diagnostic Centre Ltd rank vs peers in Healthcare Services?

Pro feature

1Vijaya Diagnostic Centre Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Vijaya Diagnostic Centre Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio